[Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease].

Lukhanina EP, Karaban' IN, Burenok IuA, Mel'nik NA, Berezetskaia NM

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2004Cited by 3 (Europe PMC)

PMID15347036PepBankPUB-15347036

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In Parkinson's disease patients whose EEG indices differed from normal values, Cerebrolysin plus levodopa strengthened auditory postexcitatory inhibition during paired stimulation.
In plain wordsIn Parkinson's disease patients whose EEG indices differed from normal, Cerebrolysin plus levodopa strengthened auditory inhibition compared with baseline.
Peptide
Cerebrolysin
Outcome
IncreaseAuditory postexcitatory inhibition
Study
n = 13
Outcome group
Brain and neuronal activity · Nervous system and cognition
Measurements
Patients with change
68%
postexcitatory inhibition
Source sentences
Summary
strengthening of postexcitatory inhibition in auditory system at the paired stimulation (13 patients, 68%).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at investigating in patients with Parkinson's disease (PD) influence of Cerebrolysin infusions (intravenously, 10 ml during 10 days) combined with levodopa treatment
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-1534703605
02HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In Parkinson's disease patients whose EEG indices differed from normal values, Cerebrolysin plus levodopa decreased P300 latency from 419.4 +/- 23.5 to 356.3 +/- 18.4 ms.
In plain wordsIn Parkinson's disease patients whose EEG indices differed from normal, Cerebrolysin plus levodopa shortened P300 latency compared with baseline.
Peptide
Cerebrolysin
Outcome
DecreaseP300 latency
Study
n = 8
Outcome group
Brain and neuronal activity · Nervous system and cognition
Measurements
P300 latency
419.4 ms
before
P300 latency
356.3 ms
after
Patients with change
42%
P300 latency
Plus/minus uncertainty in P300 latency, type not stated
23.5 ms
Before cerebrolysin plus levodopa, parent latency 419.4 ms
Plus/minus uncertainty in P300 latency, type not stated
18.4 ms
After cerebrolysin plus levodopa, parent latency 356.3 ms
Source sentences
Summary
a decrease of P300 latency from 419.4 +/- 23.5 to 356.3 +/- 18.4 ms (8 patients, 42%)
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at investigating in patients with Parkinson's disease (PD) influence of Cerebrolysin infusions (intravenously, 10 ml during 10 days) combined with levodopa treatment
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-1534703601
03HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In Parkinson's disease patients whose EEG indices differed from normal values, Cerebrolysin plus levodopa increased CNV mean amplitude 2-fold.
In plain wordsIn Parkinson's disease patients whose EEG indices differed from normal, Cerebrolysin plus levodopa raised CNV mean amplitude compared with baseline.
Peptide
Cerebrolysin
Outcome
IncreaseCNV mean amplitude
Study
n = 8
Outcome group
Brain and neuronal activity · Nervous system and cognition
Measurements
CNV mean amplitude increase
2 fold
treated patients
Patients with change
42%
CNV amplitude and square, cerebrolysin plus levodopa
Source sentences
Summary
2-fold increase of CNV mean amplitude and 3-fold increase of CNV square (8 patients, 42%) and
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at investigating in patients with Parkinson's disease (PD) influence of Cerebrolysin infusions (intravenously, 10 ml during 10 days) combined with levodopa treatment
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-1534703603
04HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In Parkinson's disease patients whose EEG indices differed from normal values, Cerebrolysin plus levodopa increased CNV square 3-fold.
In plain wordsIn Parkinson's disease patients whose EEG indices differed from normal, Cerebrolysin plus levodopa raised CNV square compared with baseline.
Peptide
Cerebrolysin
Outcome
IncreaseCNV square
Study
n = 8
Outcome group
Brain and neuronal activity · Nervous system and cognition
Measurements
CNV square increase
3 fold
treated patients
Patients with change
42%
CNV amplitude and square
Source sentences
Summary
2-fold increase of CNV mean amplitude and 3-fold increase of CNV square (8 patients, 42%) and
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at investigating in patients with Parkinson's disease (PD) influence of Cerebrolysin infusions (intravenously, 10 ml during 10 days) combined with levodopa treatment
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-1534703604
05HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In Parkinson's disease patients whose EEG indices differed from normal values, Cerebrolysin plus levodopa increased CNV duration from 423.1 +/- 93.3 to 600.6 +/- 38.5 ms.
In plain wordsIn Parkinson's disease patients whose EEG indices differed from normal, Cerebrolysin plus levodopa lengthened CNV duration compared with baseline.
Peptide
Cerebrolysin
Outcome
IncreaseCNV duration
Study
n: not reported in source
Outcome group
Brain and neuronal activity · Nervous system and cognition
Measurements
CNV duration
423.1 ms
before
CNV duration
600.6 ms
after
Plus/minus uncertainty in CNV duration, type not stated
93.3 ms
Before cerebrolysin plus levodopa, parent duration 423.1 ms
Plus/minus uncertainty in CNV duration, type not stated
38.5 ms
After cerebrolysin plus levodopa, parent duration 600.6 ms
Source sentences
Summary
an increase of CNV duration from 423.1 +/- 93.3 to 600.6 +/- 38.5 ms
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed at investigating in patients with Parkinson's disease (PD) influence of Cerebrolysin infusions (intravenously, 10 ml during 10 days) combined with levodopa treatment
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-1534703602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.